Liver transplant study tests Lower-Dose immune drugs to prevent deadly Graft-Versus-Host disease
NCT ID NCT05238155
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 100 liver transplant patients to see if using less immune-suppressing medication could lower the risk of graft-versus-host disease (GVHD), a serious condition where donor cells attack the recipient's body. Researchers tracked how many patients developed GVHD or experienced organ rejection within one year after transplant. The goal was to find a safer balance between preventing rejection and avoiding GVHD.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Methodist Dallas Medical Center
Dallas, Texas, 75203, United States